1. Merck Sharp + Dohme Corp. (18 from 2,405 patents)

2. Schering Corporation (10 from 1,829 patents)

3. Takeda Pharmaceutical Company Limited (2 from 1,177 patents)

4. Biogen, Incorporated (1 from 130 patents)

5. Shire Human Genetic Therapies, Inc. (1 from 86 patents)

6. Merck Gmbh (1 from 17 patents)

1. 12441724 - Inhibitors of plasma kallikrein and uses thereof

2. 11352356 - Inhibitors of plasma kallikrein and uses thereof

3. 10730874 - Inhibitors of plasma kallikrein and uses thereof

4. 9351965 - Indazole derivatives useful as ERK inhibitors

5. 9242981 - Fused pyrazole derivatives as novel ERK inhibitors

6. 9206142 - Anilinopiperazine derivatives and methods of use thereof

7. 9062071 - Substituted piperidines as HDM2 inhibitors

8. 8999966 - Compounds that are ERK inhibitors

9. 8999957 - Heterocyclic compounds as ERK inhibitors

10. 8946216 - Indazole derivatives useful as ERK inhibitors

11. 8889683 - Substituted quinoxalines as inhibitors of fatty acid binding protein

12. 8859776 - Substituted piperidines that increase p53 activity and the uses thereof

13. 8815875 - Inhibitors of fatty acid binding protein (FABP)

14. 8759357 - Inhibitors of fatty acid binding protein (FABP)

15. 8716483 - Compounds that are ERK inhibitors